Delving into the Latest Updates on Interferon alpha(GlaxoSmithKline Biologicals SA) with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

Interferon Alfa (NAMALWA), Interferon Alfa-nl (GlaxoSmithKline Biologicals SA), Interferon-α NAMALWA

+ [3]

Target

IFNAR

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [6]

Active Indication

Subacute Sclerosing PanencephalitisCompensated cirrhosisParaparesis, Tropical Spastic+ [6]

Inactive Indication-

Originator Organization

GlaxoSmithKline Biologicals SA

Active Organization

Sumitomo Pharma Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (09 Oct 1996),

Hairy Cell LeukemiaHepatitis B, ChronicHepatitis C, Chronic+ [3]

RegulationOrphan Drug (JP)

Login to view timeline

Structure/Sequence

Sequence Code 1101600501

Source: *****

Sequence Code 1101600502

Source: *****

Thermal therapy (hyperthermia, or heat) increases chemotherapy cancer cell kill. By itself, thermal therapy can also kill cancer cells. Whole body thermal therapy is a systemic treatment; whole-body fever-range thermal therapy can safely treat cancer cells wherever they are throughout the entire body. In this study, we are testing the combination of fever-range heat treatment and chemotherapy to test 1) The response of three types of cancer (small-cell lung, neuroendocrine cancer, lung cancer, and gastric cancer) to the thermo-chemotherapy improves cancer response compared to the effect of only chemotherapy drugs in current use; 2) whether the thermo-chemotherapy treatment helps the person's own body fight the cancer cells; and 3) whether this treatment is safe and comfortable for the patient. This study does not offer heat treatment alone. Any patient with inoperable or metastatic small cell lung cancer, neuroendocrine cancer (any organ), gastric cancer, or lung cancer, can be treated with the Phase II protocol therapy; however, the patient will need to undergo selected medical tests to make sure this treatment would be safe for them.

Start Date01 Jul 2002

Sponsor / Collaborator

University of Texas Health Science Center at Houston

NCT00277017

/ CompletedPhase 1/2IIT

A Phase I/II Trial of Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, and Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma.

The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment. We also wish to see if the addition of Thalidomide will increase the effectiveness of the already established treatment regimen.

Start Date01 Sep 2000

Sponsor / Collaborator

New Mexico Cancer Care Alliance

100 Clinical Results associated with Interferon alpha(GlaxoSmithKline Biologicals SA)

Login to view more data

100 Translational Medicine associated with Interferon alpha(GlaxoSmithKline Biologicals SA)

Login to view more data

100 Patents (Medical) associated with Interferon alpha(GlaxoSmithKline Biologicals SA)

Login to view more data

32

Literatures (Medical) associated with Interferon alpha(GlaxoSmithKline Biologicals SA)

01 Dec 2024·Annals of Plastic Surgery

Application Discrepancies in the 2023–2024 Integrated Plastic Surgery Match

Article

Author: Nazir, Niaman ; Butterworth, James ; Guest, Rachel ; Godbe, Kerilyn N. ; Egan, Katie ; Farmer, Rebecca ; Sinik, Lauren M. ; Mathes, David

BackgroundThe Plastic Surgery Common Application (PSCA) was introduced in the 2020–2021 integrated plastic surgery match cycle. We investigated the accuracy of medical student–reported quantitative metrics in the PSCA.MethodsQuantifiable data from 1 year of PSCA applications were compared between matched and unmatched students. Discrepancies were identified by reviewing publicly available data and from Electronic Residency Application Service (ERAS) applications.ResultsA total of 330 PSCAs were analyzed and divided into two groups: matched (n = 196) and unmatched (n = 134). Of the 71 medical schools with multiple applicants, 23.9% (17/71) and 31.0% (22/71) had contradicting reports of Alpha Omega Alpha and Gold Humanism Honor Society availability. Three matched applicants, with an average numeric Step 1 score of 228, reported scores as “pass.” Four applicants did not disclose a prior failing Step 1 score. More matched students had research discrepancies than unmatched students for first author (56%, 111/196; 50%, 67/132; P = 0.24) and total publications (66.8%, 131/196; 53%, 71/134; P = 0.011). The mean discrepancy number between matched and unmatched students was similar for first author (3.0 vs 3.2, P = 0.61) and total publications (4.3 vs 4.5, P = 0.61). Reasons for discrepancies included counting accepted articles (20.2%), submitted articles (7.5%), non–peer reviewed (3.1%) articles, and other endeavors (6.2%) in publication counts, with 52% of applicants having multiple reasons for discrepancies.ConclusionsMatched and unmatched applicants applying to plastic surgery had honor society and Step 1 score discrepancies, and inaccurate research reporting. NBME score verification and PubMed indexing may be a warranted addition to PSCA applications to guarantee application consistency.

01 Oct 2020·Journal of the American Academy of Orthopaedic Surgeons

Evaluating the Standardized Letter of Recommendation Form in Applicants to Orthopaedic Surgery Residency

Article

Author: Levine, William N ; Lieberman, Jay R ; Kang, Hyunwoo Paco ; Robertson, Djani M

Introduction:A standardized letter of recommendation (SLOR) form for orthopaedic surgery residency programs has recently been adopted for use, but it has not been scientifically evaluated. The purpose of this study is to investigate the usefulness of the SLOR form in the selection process.Methods:All SLOR forms submitted to our institution over a single application cycle were extracted and analyzed. The United States Medical Licensing Examination Step 1 scores, grades in clinical rotations, Alpha Omega Alpha status, and the number of publications were recorded for each applicant. Correlations were calculated with Spearman rho, and inter-rater reliability was evaluated by calculating intraclass correlation coefficients.Results:One thousand one hundred thirty-seven SLOR forms were analyzed for 513 applicants. There was substantial rank inflation with the SLOR form; the majority (92%) of applicants were rated as either ranked to match or in the top one-third of their rank list. Objective applicant factors such as grades and Step 1 scores demonstrated a very weak to nonexistent correlation with the summative rank (rho 0.07 to 0.13, P ≤ 0.012). Poor inter-rater reliability was observed with the intraclass correlation coefficient ranging from 0.22 to 0.33 (P < 0.001).Conclusions:The usefulness of the SLOR form is limited by the very high ratings observed for all questions, and in particular, the final summative rank. Measures to reduce rank inflation must be implemented to improve the discriminant ability of the SLOR form, and if this cannot be accomplished, perhaps the form should be abandoned.Level of Evidence:Level III Retrospective

01 May 2020·Academic Medicine

Suspending Student Selections to Alpha Omega Alpha Honor Medical Society: How One School Is Navigating the Intersection of Equity and Wellness

Article

Author: Muller, David ; Palermo, Ann-Gel ; Holloway, Terrell ; Lynch, Giselle

Medical education must provide students with a delicate balance of academic rigor, equity, and wellness. While the medical education community espouses all these values, the authors believe the way medical students are evaluated and rewarded undermines equity and wellness. Alpha Omega Alpha Honor Medical Society (AΩA) membership is arguably the highest honor that a medical student can achieve. In the short term, it opens doors to the most selective training opportunities, and in the long term, ushers students into an elite group of future physician leaders. Yet recent data have demonstrated that AΩA is disproportionately awarded to white students.At Icahn School of Medicine at Mount Sinai (ISMMS), the authors observed that students underrepresented in science and medicine were persistently underrepresented among those selected for AΩA. They describe efforts at ISMMS to reduce bias in the selection process and the ultimate decision to suspend medical student selection for AΩA altogether. The authors argue that selection to AΩA reinforces the structural biases and social privilege that are embedded in medical education and undermines the ability to deliver an educational experience that has as its core tenets equity and wellness. Suspending participation in student selection for AΩA is an important step toward recognizing that medical school learning environments continue to privilege white students over students who are underrepresented in medicine.

100 Deals associated with Interferon alpha(GlaxoSmithKline Biologicals SA)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB06	DB00011

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Subacute Sclerosing Panencephalitis	JP	Sumitomo Pharma Co., Ltd.	12 Jul 2017
Compensated cirrhosis	JP	Sumitomo Pharma Co., Ltd.	16 Oct 2008
Paraparesis, Tropical Spastic	JP	Sumitomo Pharma Co., Ltd.	18 Jan 2000
Hairy Cell Leukemia	JP	Sumitomo Pharma Co., Ltd.	09 Oct 1996
Hepatitis B, Chronic	JP	Sumitomo Pharma Co., Ltd.	09 Oct 1996
Hepatitis C, Chronic	JP	Sumitomo Pharma Co., Ltd.	09 Oct 1996
Kidney Neoplasms	JP	Sumitomo Pharma Co., Ltd.	09 Oct 1996
Multiple Myeloma	JP	Sumitomo Pharma Co., Ltd.	09 Oct 1996
Philadelphia chromosome positive chronic myelogenous leukemia	JP	Sumitomo Pharma Co., Ltd.	09 Oct 1996